2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-152899
    Selachyl alcohol 593-31-7 ≥98.0%
    Selachyl alcohol is an orally active antihypertensive agent. Selachyl alcohol has similar activities with antihypertensive neutral renomedullary lipid (ANRL). Selachyl alcohol is an alkylglycerol compound in shark liver oil mixture with properties that reduce lung metastasis. Selachyl alcohol can be used for cardiovascular disease research.
    Selachyl alcohol
  • HY-15293A
    JTV-519 free base 145903-06-6 98%
    JTV-519 free base (K201 free base) is a Ca2+-dependent blocker of sarcoplasmic reticulum Ca2+-stimulated ATPase (SERCA) and a partial agonist of ryanodine receptors in striated muscle. Antiarrhythmic and cardioprotective properties.
    JTV-519 free base
  • HY-153098
    ARC186
    ARC186 (sodium) is an unconjugated 40KDa PEG aptamer with a sequence identical to HY-147080 Avacincaptad pegol (ARC1905) sodium. ARC1905 is highly potent complement inhibitors that function by blocking the convertase-catalyzed activation of C5.
    ARC186
  • HY-157220
    Tolvaptan phosphate ester sodium 942619-79-6 99.85%
    Tolvaptan phosphate ester sodium, a prodrug of Tolvaptan (HY-17000), can be used in the study of cardiac edema. Tolvaptan is a selective, competitive and orally active vasopressin receptor 2 (V2R) antagonist with an IC50 of 1.28 μM for the inhibition of arginine vasopressin (AVP)-induced platelet aggregation.
    Tolvaptan phosphate ester sodium
  • HY-15895S
    Aprocitentan-d4
    Aprocitentan-d4 is a deuterium labeled Aprocitentan. Aprocitentan is a major and pharmacologically active metabolite of Macitentan. Aprocitentan is an orally active dual ETA/ETB antagonist with IC50s of 3.4 nM and 987 nM, and pA2 valus of 6.7 and 5.5, respectively. Aprocitentan is an antihypertensive agent.
    Aprocitentan-d4
  • HY-161939
    7030B-C5 370871-42-4 99.78%
    7030B-C5 is a PCSK9 inhibitor (IC50=1.61 μM). 7030B-C5 can significantly reduce plasma cholesterol and triglyceride (TG) levels in vivo and slow the progression of atherosclerosis. 7030B-C5 can be used in the study of cardiovascular diseases.
    7030B-C5
  • HY-162109
    Thrombin inhibitor 11 99.77%
    Thrombin inhibitor 11 is a thrombin inhibitor, with human and rat Ki values of 65 nM and 10.3 nM, respectively.
    Thrombin inhibitor 11
  • HY-163438
    BKIDC-1553 1951431-34-7 99.65%
    BKIDC-1553 is an orally active antiglycolytic agent and a bumped kinase inhibitor derived compound with a predicted ~17 h half-life in human. BKIDC-1553 inhibits CYP2C8 and Angiotensin Converting Enzyme and can be used for cancer research.
    BKIDC-1553
  • HY-164704
    JA2 277333-45-6 99.94%
    JA2 is an inhibitor of metalloendopeptidase 24.15 that can potentiate the hypotensive response to bradykinin in rat.
    JA2
  • HY-165578
    Neladenoson 1239234-36-6 99.95%
    Neladenoson is a potent and selective Adenosine A1 Receptor agonist. EGFR-IN-162 is promising for research of heart failure.
    Neladenoson
  • HY-173591
    T0080 2785323-68-2 98%
    T0080 is a FPR-1 antagonist. T0080 reduces the cell apoptosis, inhibits ROS production and pro-inflammatory cytokines (TNF-α and IL-1β) from plaque macrophages, which attenuates atherosclerotic progression in ApoE−/− mice.
    T0080
  • HY-17376R
    Ezetimibe (Standard) 163222-33-1 99.90%
    Ezetimibe (Standard) is the analytical standard of Ezetimibe. This product is intended for research and analytical applications. Ezetimibe (SCH 58235) is a potent cholesterol absorption inhibitor. Ezetimibe is a Niemann-Pick C1-like1 (NPC1L1) inhibitor, and is a potent Nrf2 activator.
    Ezetimibe (Standard)
  • HY-17468R
    Bumetanide (Standard) 28395-03-1
    Bumetanide (Standard) is the analytical standard of Bumetanide. This product is intended for research and analytical applications. Bumetanide (Ro 10-6338; PF 1593), a highly potent loop diuretic, is a Na+-K+-Cl+ cotransporter (NKCC) blocker. Bumetanide is a selective NKCC1 inhibitor, but also inhibits NKCC2, with IC50s of 0.68 μM and 4.0 μM for hNKCC1A and hNKCC2A, respectively.
    Bumetanide (Standard)
  • HY-17504S
    Rosuvastatin-d6 calcium 98.54%
    Rosuvastatin-d6 (calcium) is deuterium labeled Rosuvastatin.
    Rosuvastatin-d6 calcium
  • HY-17505R
    Candesartan Cilexetil (Standard) 145040-37-5
    Candesartan Cilexetil (Standard) is the analytical standard of Candesartan Cilexetil. This product is intended for research and analytical applications. Candesartan Cilexetil (TCV-116) is an angiotensin II receptor inhibitor. Candesartan Cilexetil ameliorates the pulmonary fibrosis and has antiviral and skin wound healing effect. Candesartan Cilexetil can be used for the research of high blood pressure.
    Candesartan Cilexetil (Standard)
  • HY-17512S
    Losartan-d4 1030937-27-9 99.93%
    Losartan-d4 is the deuterium labeled Losartan. Losartan is an angiotensin II receptor antagonist, competing with the binding of angiotensin II to AT1 receptors with IC50 of 20 nM.
    Losartan-d4
  • HY-18725A
    P2X7-IN-2 TFA 99.93%
    P2X7-IN-2 TFA (compound 58) is a P2X7 receptor inhibitor. P2X7-IN-2 TFA inhibits IL-Iβ release with an IC50 value of 0.01 nM. P2X7-IN-2 TFA can be used for the research of autoimmunity, inflammation and cardiovascular disease.
    P2X7-IN-2 TFA
  • HY-30004R
    1-Aminocyclopropane-1-carboxylic acid (Standard) 22059-21-8
    1-Aminocyclopropane-1-carboxylic acid (Standard) is the analytical standard of 1-Aminocyclopropane-1-carboxylic acid. This product is intended for research and analytical applications. 1-Aminocyclopropane-1-carboxylic acid is an endogenous metabolite. In the presence of low concentrations (1 μM) of glutamate, 1-Aminocyclopropane-1-carboxylic acid acts as a small molecule agonist of NMDA receptors with an EC50 of 0.7-0.9 μM. At high concentrations (10 μM) of glutamate, 1-Aminocyclopropane-1-carboxylic acid acts as a competitive antagonist of NMDA receptors with an EC50 of 81.6 nM. 1-Aminocyclopropane-1-carboxylic acid exerts neuroprotective activity by moderately activating NMDA receptors to prevent neuronal cell death in ischemic animal models. Additionally, 1-Aminocyclopropane-1-carboxylic acid is an antagonist of NMDA receptors, inducing blood pressure reduction and antioxidant effects in stroke-prone hypertensive rats. 1-Aminocyclopropane-1-carboxylic acid enhances object recognition memory and cognitive flexibility dependent on the prefrontal cortex, but does not affect impulsivity nor exhibit an antipsychotic-like profile. 1-Aminocyclopropane-1-carboxylic acid shows promise for research in the field of neurotoxicity..
    1-Aminocyclopropane-1-carboxylic acid (Standard)
  • HY-90009D
    (6S,12aR)-Tadalafil 171596-28-4 99.34%
    (6S,12aR)-Tadalafil (Tadalafil EP Impurity C) is a highly potent PDE5 inhibitor with an IC50 value of 5 nM and has blood pressure lowering activity.
    (6S,12aR)-Tadalafil
  • HY-A0043A
    Cilazapril monohydrate 92077-78-6 99.94%
    Cilazapril Monohydrate is a angiotensin-converting enzyme (ACE) inhibitor used for the treatment of hypertension and congestive heart failure.
    Cilazapril monohydrate
Cat. No. Product Name / Synonyms Application Reactivity